Safety and effectiveness of efgartigimod in patients with generalized myasthenia gravis by autoantibody subtype: analysis of post-marketing surveillance in Japan
Efgartigimod for intravenous infusion (efgartigimod-IV) is approved in Japan for generalized myasthenia gravis (gMG) regardless of autoantibody subtypes, whereas the approvals in other countries are restricted to only anti-acetylcholine receptor antibody (AChR-Ab) positive. Post-marketing surveillance was conducted...